## Carolyn Nessim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2595345/publications.pdf

Version: 2024-02-01

623734 580821 14 49 757 25 citations g-index h-index papers 56 56 56 892 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. Annals of Surgical Oncology, 2021, 28, 7873-7888.	1.5	105
2	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. Clinical Cancer Research, 2019, 25, 2664-2671.	7.0	80
3	Dual inhibition of Wnt and Yesâ€associated protein signaling retards the growth of tripleâ€negative breast cancer in both mesenchymal and epithelial states. Molecular Oncology, 2018, 12, 423-440.	4.6	54
4	Radioactive Seed Localization Versus Wire-Guided Localization for Nonpalpable Breast Cancer: A Cost and Operating Room Efficiency Analysis. Annals of Surgical Oncology, 2017, 24, 3567-3573.	1.5	51
5	Immunotherapy for sarcomas: new frontiers and unveiled opportunities. , 2021, 9, e001580.		48
6	Co-inhibition of mTORC1, HDAC and ESR1 $\hat{l}_{\pm}$ retards the growth of triple-negative breast cancer and suppresses cancer stem cells. Cell Death and Disease, 2018, 9, 815.	6.3	34
7	Early and Late Complications of Percutaneous Core Needle Biopsy of Retroperitoneal Tumors at Two Tertiary Sarcoma Centers. Annals of Surgical Oncology, 2019, 26, 4692-4698.	1.5	31
8	Defining the role of neoadjuvant systemic therapy in highâ€risk retroperitoneal sarcoma: A multiâ€institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Cancer, 2021, 127, 729-738.	4.1	30
9	Both bulk and cancer stem cell subpopulations in tripleâ€negative breast cancer are susceptible to Wnt, <scp>HDAC</scp> , and <scp>ER</scp> α coinhibition. FEBS Letters, 2016, 590, 4606-4616.	2.8	28
10	Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). Annals of Surgical Oncology, 2021, 28, 2705-2714.	1.5	26
11	The effect of fluid overload in the presence of an epidural on the strength of colonic anastomoses. Journal of Surgical Research, 2013, 183, 567-573.	1.6	21
12	Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG. Cancer, 2020, 126, 4917-4925.	4.1	21
13	Activating Transcription Factor 3 as a Novel Regulator of Chemotherapy Response in Breast Cancer. Translational Oncology, 2018, 11, 988-998.	3.7	20
14	Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Annals of Surgical Oncology, 2021, 28, 7854-7863.	1.5	19
15	Retroperitoneal Sarcoma Care in 2021. Cancers, 2022, 14, 1293.	3.7	17
16	How Often do Level III Nodes Bear Melanoma Metastases and does it Affect Patient Outcomes?. Annals of Surgical Oncology, 2013, 20, 2056-2064.	1.5	16
17	Wait Times for Breast Cancer Surgery: Effect of Magnetic Resonance Imaging and Preoperative Investigations on the Diagnostic Pathway. Journal of Oncology Practice, 2015, 11, e131-e138.	2.5	16
18	Surgical Site Infection Prevention: A Qualitative Analysis of an Individualized Audit and Feedback Model. Journal of the American College of Surgeons, 2012, 215, 850-857.	0.5	14

#	Article	IF	CITATIONS
19	Wait Times for Melanoma Surgery: Is There an Association with Overall Survival?. Annals of Surgical Oncology, 2018, 25, 265-270.	1.5	14
20	Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. Annals of Surgical Oncology, 2021, 28, 6882-6889.	1.5	14
21	Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence. Annals of Surgical Oncology, 2020, 27, 3683-3691.	1.5	13
22	Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Annals of Surgical Oncology, 2022, 29, 7335-7348.	1.5	13
23	Socioeconomic Status and Melanoma in Canada: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2021, 25, 87-94.	1.2	9
24	Squamous Cell Carcinoma with Regional Metastasis to Axilla or Groin Lymph Nodes: a Multicenter Outcome Analysis. Annals of Surgical Oncology, 2019, 26, 4642-4650.	1.5	7
25	Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review. Cancers, 2021, 13, 1905.	3.7	7
26	Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. Cancers, 2021, 13, 2282.	3.7	6
27	Going Beyond the Numerical Scoresheet: Identifying Maladaptive Narcissistic Traits in Residency Applicants. Journal of Surgical Education, 2019, 76, 65-76.	2.5	4
28	ASO Visual Abstract: An Analysis ofÂDifferentiationÂChangesÂand Outcomes at theÂFirstÂRecurrence of RetroperitonealÂLiposarcoma by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Annals of Surgical Oncology, 2021, 28, 490-491.	1.5	4
29	Perioperative blood transfusion is not an independent predictor for worse outcomes in retroperitoneal sarcoma surgery. European Journal of Surgical Oncology, 2021, 47, 1763-1770.	1.0	4
30	Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. Annals of Surgical Oncology, 2022, 29, 5937-5945.	1.5	4
31	Primary mesenteric sarcomas: Collaborative experience from the Transâ€Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Journal of Surgical Oncology, 2021, 123, 1057-1066.	1.7	3
32	Can MRI accurately identify which patients with operable breast cancer will have a pathologic complete response after neoadjuvant therapy?. Journal of Clinical Oncology, 2012, 30, 616-616.	1.6	3
33	Current management of benign retroperitoneal tumors. European Journal of Surgical Oncology, 2023, 49, 1081-1090.	1.0	3
34	Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1365-1378.	2.5	2
35	Preoperative imaging of gastric GISTs underestimates pathologic tumor size: A retrospective, single institution analysis. Journal of Surgical Oncology, 2021, 124, 49-58.	1.7	2
36	Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional TARPSWG study Journal of Clinical Oncology, 2020, 38, 11513-11513.	1.6	2

#	Article	IF	CITATIONS
37	Innovative practice model to optimize resource utilization and improve access to care for high-risk and BRCA+ patients. Canadian Journal of Surgery, 2017, 60, 37-44.	1.2	2
38	When Is Watchful Waiting Warranted? Advances in Soft Tissue Sarcomaâ€"An Editorial Commentary. Annals of Surgical Oncology, 2019, 26, 3420-3422.	1.5	1
39	Restructuring Skin Cancer Care in Ontario: A Provincial Plan. Current Oncology, 2021, 28, 1183-1196.	2.2	1
40	ASO Author Reflections: Selecting Patients for Recurrent Retroperitoneal Sarcoma Surgery: The Challenging Trade-Off Between Oncologic Outcome and Morbidity. Annals of Surgical Oncology, 2021, 28, 852-853.	1.5	1
41	Impact of surveillance-detected metastatic recurrence on treatment outcomes of high-risk melanoma Journal of Clinical Oncology, 2018, 36, e21612-e21612.	1.6	1
42	Malignant melanoma arising from an end ileostomy. BMJ Case Reports, 2019, 12, e230265.	0.5	1
43	Extent of Groin Dissection in Melanoma: A Mixed-Methods, Population-Based Study of Practice Patterns and Outcomes. Current Oncology, 2021, 28, 5422-5433.	2.2	1
44	ASO Author Reflections: Wait Times for Melanoma Surgery. Annals of Surgical Oncology, 2018, 26, 527-528.	1.5	0
45	Impact of Positive Biopsy Margins and Residual Disease in Wide Local Excision (WLE) on Melanoma Survival: Implications for Management. Journal of the American College of Surgeons, 2020, 231, e208.	0.5	0
46	The Association Between Socio-Economic Status and Survival Outcomes for Melanoma in Canada. Journal of the American College of Surgeons, 2020, 231, S282-S283.	0.5	0
47	Is it time for a change in the model of care for AYA patients with soft tissue sarcoma? How to improve outcomes for patients aged 15-25 using a mixed pediatric-adult cancer care model in expert sarcoma centers. European Journal of Surgical Oncology, 2020, 46, 1201-1202.	1.0	0
48	CLO20-051: LYMPHA: Eliminating the Burden of Lymphedema in Cancer Patients Requiring Nodal Dissections. A Pilot Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, CLO20-051.	4.9	0
49	Sentinel lymph node biopsy in Merkel cell carcinoma: A multi-institutional study from the Pan-Canadian Merkel Cell Collaborative Journal of Clinical Oncology, 2022, 40, 9583-9583.	1.6	O